2. Academic Validation
  3. Therapeutic targeting of HYPDH/PRODH2 with N-propargylglycine offers a Hyperoxaluria treatment opportunity

Therapeutic targeting of HYPDH/PRODH2 with N-propargylglycine offers a Hyperoxaluria treatment opportunity

  • Biochim Biophys Acta Mol Basis Dis. 2024 Jan;1870(1):166848. doi: 10.1016/j.bbadis.2023.166848.
Joanna Bons 1,  Ada Tadeo 1,  Gary K Scott 1,  Fadzai Teramayi 1,  John J Tanner 2,  Birgit Schilling 1,  Christopher C Benz 1,  Lisa M Ellerby 3
Affiliations

Affiliations

  • 1 Buck Institute for Research on Aging, Novato, CA, USA.
  • 2 Departments of Biochemistry and Chemistry, University of Missouri, Columbia, MO, USA.
  • 3 Buck Institute for Research on Aging, Novato, CA, USA. Electronic address: [email protected].
PMID: 37586438 DOI: 10.1016/j.bbadis.2023.166848
Abstract

N-propargylglycine prevents 4-hydroxyproline catabolism in mouse liver and kidney. N-propargylglycine is a novel suicide inhibitor of PRODH2 and induces mitochondrial degradation of PRODH2. PRODH2 is selectively expressed in liver and kidney and contributes to primary hyperoxaluria (PH). Preclinical evaluation of N-propargylglycine efficacy as a new PH therapeutic is warranted.

Keywords

4-hydroxyproline (Hyp); 4-hydroxyproline dehydrogenase (HYPDH/PRODH2); N-propargylglycine (N-PPG); Primary hyperoxaluria (PH).

Figures
Products